
V5med Inc. is a Taiwanese smart medical startup specializing in AI medical image recognition technology and clinical applications. It is invested by V5 Technologies, a leader in optical defect detection in the semiconductor industry with over a decade of expertise in high-speed image processing, deep learning, and computer vision. V5med leverages this strong technical foundation to develop AI-assisted diagnostic platforms centered on low-dose CT (LDCT) for lung health, including lung nodules, emphysema, fibrosis, and coronary artery calcium (CAC) analysis. The company obtained Taiwan TFDA medical device certification in 2022 and U.S. FDA 510(k) clearance in 2025, becoming the first Taiwanese firm with FDA approval for lung AI diagnostic software. Its products are deployed in Taiwan, Japan, Vietnam, Thailand, and Indonesia, collaborating with top medical institutions and distributors. V5med aims to be a leading Asian smart medical brand advancing precision medicine through AI-assisted diagnostics.

V5med Inc. is a Taiwanese smart medical startup specializing in AI medical image recognition technology and clinical applications. It is invested by V5 Technologies, a leader in optical defect detection in the semiconductor industry with over a decade of expertise in high-speed image processing, deep learning, and computer vision. V5med leverages this strong technical foundation to develop AI-assisted diagnostic platforms centered on low-dose CT (LDCT) for lung health, including lung nodules, emphysema, fibrosis, and coronary artery calcium (CAC) analysis. The company obtained Taiwan TFDA medical device certification in 2022 and U.S. FDA 510(k) clearance in 2025, becoming the first Taiwanese firm with FDA approval for lung AI diagnostic software. Its products are deployed in Taiwan, Japan, Vietnam, Thailand, and Indonesia, collaborating with top medical institutions and distributors. V5med aims to be a leading Asian smart medical brand advancing precision medicine through AI-assisted diagnostics.